



I-MAB
BIOPHARMA

I-Mab to Participate at the Jefferies Global Healthcare Conference

May 22, 2024

ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.

Jefferies Global Healthcare Conference

Presentation Time	Wednesday, June 5 at 9:30 a.m. EST
Presenters	Raj Kannan, CEO; Louie Naumovski, Interim CMO
Webcast link	Here
Meetings	One-on-one and small group meetings: June 5, 2024
Management Participants	Raj Kannan, CEO Joe Skelton, CFO Louie Naumovski, Interim CMO Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab's IR website at <https://ir.i-mabbiopharma.com/>

For more information, please contact your Jefferies representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit <https://ir.i-mabbiopharma.com/> and follow us on LinkedIn and X.

For more information, please contact:

Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com

View original content to download multimedia: <https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-jefferies-global-healthcare-conference-302150438.html>

SOURCE I-Mab Biopharma